The clinical challenges of akathisia

CNS Spectrums

Volumn 20, Issue S1, 2015, Pages 4-14

  Lohr, James B ^a,b   Eidt, Carolyn A ^a,b   Alfaraj, Areej Abdulrazzaq ^a   Soliman, Mounir A ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

akathisia; antipsychotic; movement disorder; Parkinson; review

Indexed keywords

ANTIDEPRESSANT AGENT; NEUROLEPTIC AGENT;

AGITATION; AKATHISIA; ANXIETY; CLINICAL FEATURE; DIAGNOSTIC ERROR; DIFFERENTIAL DIAGNOSIS; DISEASE ASSOCIATION; DISEASE CLASSIFICATION; DYSTONIA; GILLES DE LA TOURETTE SYNDROME; HUMAN; PARKINSONISM; PATHOPHYSIOLOGY; PHARMACEUTICAL CARE; PHENOMENOLOGY; PRIORITY JOURNAL; RESTLESS LEGS SYNDROME; RESTLESSNESS; REVIEW; RISK FACTOR; SYMPTOM ASSESSMENT; TARDIVE DYSKINESIA; TIC; TREATMENT PLANNING; TREMOR; PSYCHOMOTOR AGITATION;

HUMANS; PSYCHOMOTOR AGITATION;

EID: 84951186515     PISSN: 10928529     EISSN: None     Source Type: Journal    
DOI: 10.1017/S1092852915000838     Document Type: Review

References (108)

1. Berrios GE. Lad Haskovec and akathisia: an introduction. Hist Psychiatry. 1995; 6(22): 243-245.
2. Mohr P, Volavka J. Ladislav Haskovec and akathisia: 100th anniversary. Br J Psychiatry. 2002; 181(6): 537.
3. Sachdev P. The development of the concept of akathisia: a historical overview. Schizophr Res. 1995; 16(1): 33-45.
4. Baden EY, Prodany K, Wiener SW, Hoffman RS. Diphenhydramine in the treatment of akathesia induced by prochlorperazine. J Emerg Med. 2005; 28(3): 347-348.
5. Keckich WA. Neuroleptics: violence as a manifestation of akathisia. JAMA. 1978; 240(20): 2185.
6. Leong GB, Silva JA. Neuroleptic-induced akathisia and violence: a review. J Forensic Sci. 2003; 48(1): 187-189.
7. Seemuller F, Lewitzka U, Bauer M, et al. The relationship of akathisia with treatment emergent suicidality among patients with first-episode schizophrenia treated with haloperidol or risperidone. Pharmacopsychiatry. 2012; 45(7): 292-296.
8. Hansen L. A critical review of akathisia, and its possible association with suicidal behaviour. Hum Psychopharmacol. 2001; 16(7): 495-505.
9. Galynker II, Nazarian D. Akathisia as violence. J Clin Psychiatry. 1997; 58(1): 31-32.
10. Lipinski JF Jr, Mallya G, Zimmerman P, Pope HG Jr. Fluoxetineinduced akathisia: clinical and theoretical implications. J Clin Psychiatry. 1989; 50(9): 339-342.
11. Raskin DE. Akathisia: a side effect to be remembered. Am J Psychiatry. 1972; 129(3): 345-347.
12. Van Putten T. The many faces of akathisia. Compr Psychiatry. 1975; 16(1): 43-47.
13. Duncan EJ, Adler LA, Stephanides M, Sanfilipo M, Angrist B. Akathisia and exacerbation of psychopathology: a preliminary report. Clin Neuropharmacol. 2000; 23(3): 169-173.
14. Nair CJ, Josiassen RC, Abraham G, Stanilla JK, Tracy JI, Simpson GM. Does akathisia influence psychopathology in psychotic patients treated with clozapine? Biol Psychiatry. 1999; 45(10): 1376-1383.
15. Peitl MV, Proloscic J, Blazevic-Zelic S, Skarpa-Usmiani I, Peitl V. Symptoms of agitated depression and/or akathisia. Psychiatr Danub. 2011; 23(1): 108-110.
16. Lohr JB, Wisniewski AA. Movement disorders: a neuropsychiatric approach. New York: Guildford Press; 1987.
17. Lohr JB, Browning JA. Movement disorders in neuropsychiatry. Curr Opin Psychiatry. 1996; 9(1): 85-88.
18. Hirose S. Restlessness in suboccipital muscles as a manifestation of akathisia. Psychiatry Clin Neurosci. 2001; 55(1): 81-82.
19. Yamashita H, Horiguchi J, Mizuno S, Kuramoto Y, Yamawaki S, Inami Y. A case of neuroleptic-induced unilateral akathisia with periodic limb movements in the opposite side during sleep. Psychiatry Clin Neurosci. 1999; 53(2): 291-293.
20. Bratti IM, Kane JM, Marder SR. Chronic restlessness with antipsychotics. Am J Psychiatry. 2007; 164(11): 1648-1654.
21. Sachdev P. The epidemiology of drug-induced akathisia: Part II. Chronic, tardive, and withdrawal akathisias. Schizophr Bull. 1995; 21(3): 451-461.
22. Lang AE. Withdrawal akathisia: case reports and a proposed classification of chronic akathisia. Mov Disord. 1994; 9(2): 188-192.
23. Bhidayasiri R, Boonyawairoj S. Spectrum of tardive syndromes: clinical recognition and management. Postgrad Med J. 2011; 87(1024): 132-141.
24. Nishikawa T, Koga I, Uchida Y, Tanaka M. Treatment of tardive akathisia with clonidine. Kurume Med J. 1990; 37(3): 185-187.
25. Munetz MR, Cornes CL. Akathisia, pseudoakathisia and tardive dyskinesia: clinical examples. Compr Psychiatry. 1982; 23(4): 345-352.
26. Stubbs JH, Halstead SM. Pseudoakathisia: a review and two case reports. Compr Psychiatry. 2000; 41(1): 70-72.
27. Bing R. Textbook of Nervous Diseases. St. Louis, MO: C.V. Mosby; 1939.
28. Kumar R, Sachdev PS. Akathisia and second-generation antipsychotic drugs. Curr Opin Psychiatry. 2009; 22(3): 293-299.
29. Kane JM, Fleischhacker WW, Hansen L, Perlis R, Pikalov A 3rd, Assuncao-Talbott S. Akathisia: an updated review focusing on second-generation antipsychotics. J Clin Psychiatry. 2009; 70(5): 627-643.
30. Kemp DE, Gilmer WS, Fleck J, Straus JL, Dago PL, Karaffa M. Aripiprazole augmentation in treatment-resistant bipolar depression: early response and development of akathisia. Prog Neuropsychopharmacol Biol Psychiatry. 2007; 31(2): 574-577.
31. Saddichha S, Kumar R, Babu GN, Chandra P. Aripiprazole associated with acute dystonia, akathisia, and parkinsonism in a single patient. J Clin Pharmacol. 2012; 52(9): 1448-1449.
32. Spielmans GI, Berman MI, Linardatos E, Rosenlicht NZ, Perry A, Tsai AC. Adjunctive atypical antipsychotic treatment for major depressive disorder: a meta-analysis of depression, quality of life, and safety outcomes. PLoS Med. 2013; 10(3): e1001403.
33. Oh GH, Yu J-C, Choi K-S, Joo E-J, Jeong S-H. Simultaneous comparison of efficacy and tolerability of second-generation antipsychotics in schizophrenia: mixed-treatment comparison analysis based on head-to-head trial data. Psychiatry Investig. 2015; 12(1): 46-54.
34. Stahl SM. Role of alpha1 adrenergic antagonism in the mechanism of action of iloperidone: reducing extrapyramidal symptoms. CNS Spectr. 2013; 18(6): 285-288.
35. Citrome L. Iloperidone: a clinical overview. J Clin Psychiatry. 2011; 72(Suppl 1): 19-23.
36. Dargani NV, Malhotra AK. Safety profile of iloperidone in the treatment of schizophrenia. Expert Opin Drug Saf. 2014; 13(2): 241-246.
37. Tarazi FI, Stahl SM. Iloperidone, asenapine and lurasidone: a primer on their current status. Expert Opin Pharmacother. 2012; 13(13): 1911-1922.
38. Caccia S, Pasina L, Nobili A. New atypical antipsychotics for schizophrenia: iloperidone. Drug Des Devel Ther. 2010; 4: 33-48.
39. Grover S, Sahoo S. Clozapine induced akathisia: a case report and review of the evidence. Indian J Pharmacol. 2015; 47(2): 234-235.
40. Schneider C, Corrigall R, Hayes D, Kyriakopoulos M, Frangou S. Systematic review of the efficacy and tolerability of clozapine in the treatment of youth with early onset schizophrenia. Eur Psychiatry. 2014; 29(1): 1-10.
41. Cohen BM, Keck PE, Satlin A, Cole JO. Prevalence and severity of akathisia in patients on clozapine. Biol Psychiatry. 1991; 29(12): 1215-1219.
42. Wright MT. Antiemetics, akathisia, and pregnancy. Psychosomatics. 2007; 48(6): 461-466.
43. Kawanishi C, Onishi H, Kato D, et al. Unexpectedly high prevalence of akathisia in cancer patients. Palliat Support Care. 2007; 5(4): 351-354.
44. Adler LA, Angrist BM. Paroxetine and akathisia. Biol Psychiatry. 1995; 37(5): 336-337.
45. Baldassano CF, Truman CJ, Nierenberg A, Ghaemi SN, Sachs GS. Akathisia: a review and case report following paroxetine treatment. Compr Psychiatry. 1996; 37(2): 122-124.
46. Bonnet-Brilhault F, Thibaut F, Leprieur A, Petit M. A case of paroxetine-induced akathisia and a review of SSRI-induced akathisia. Eur Psychiatry. 1998; 13(2): 109-111.
47. Grover S, Valaparla VL. Venlafaxine induced akathisia: a case report. Indian J Pharmacol. 2014; 46(6): 660-661.
48. Hawthorne JM, Caley CF. Extrapyramidal reactions associated with serotonergic antidepressants. Ann Pharmacother. 2015; 49(10): 1136-1152.
49. Koliscak LP, Makela EH. Selective serotonin reuptake inhibitorinduced akathisia. J Am Pharm Assoc (2003). 2009; 49(2): e28-e36; quiz e37-28.
50. Lambert MT, Trutia C, Petty F. Extrapyramidal adverse effects associated with sertraline. Prog Neuropsychopharmacol Biol Psychiatry. 1998; 22(5): 741-748.
51. Lane RM. SSRI-Induced extrapyramidal side-effects and akathisia: implications for treatment. J Psychopharmacol. 1998; 12(2): 192-214.
52. Olivera AA. A case of paroxetine-induced akathisia. Biol Psychiatry. 1996; 39(10): 910.
53. Vandel P, Bonin B, Leveque E, Sechter D, Bizouard P. Tricyclic antidepressant-induced extrapyramidal side effects. Eur Neuropsychopharmacol. 1997; 7(3): 207-212.
54. Gill HS, De Vane CL, Risch SC. Extrapyramidal symptoms associated with cyclic antidepressant treatment: a review of the literature and consolidating hypotheses. J Clin Psychopharmacol. 1997; 17(5): 377-389.
55. Riesselman A, El-Mallakh RS. Akathisia with azithromycin. Ann Pharmacother. 2015; 49(5): 609.
56. Sachdev P. The epidemiology of drug-induced akathisia: Part I. Acute akathisia. Schizophr Bull. 1995; 21(3): 431-449.
57. Asser A, Taba P. Psychostimulants and movement disorders. Front Neurol. 2015; 6: 75.
58. Stacy M. Nonmotor symptoms in Parkinson's disease. Int J Neurosci. 2011; 121(Suppl 2): 9-17.
59. Pappa S, Dazzan P. Spontaneous movement disorders in antipsychotic-naive patients with first-episode psychoses: a systematic review. Psychol Med. 2009; 39(7): 1065-1076.
60. Brüne M. The incidence of akathisia in bipolar affective disorder treated with neuroleptics-a preliminary report. J Affect Disord. 1999; 53(2): 175-177.
61. De Fruyt J, Deschepper E, Audenaert K, et al. Second generation antipsychotics in the treatment of bipolar depression: a systematic review andmeta-analysis. J Psychopharmacol. 2012; 26(5): 603-617.
62. Kane JM, Barnes TR, Correll CU, et al. Evaluation of akathisia in patients with schizophrenia, schizoaffective disorder, or bipolar I disorder: a post hoc analysis of pooled data from short- and long-term aripiprazole trials. J Psychopharmacol. 2010; 24(7): 1019-1029.
63. Miller CH, Hummer M, Oberbauer H, Kurzthaler I, De Col C, Fleischhacker WW. Risk factors for the development of neuroleptic induced akathisia. Eur Neuropsychopharmacol. 1997; 7(1): 51-55.
64. Nordström P, Michaëlsson K, Gustafson Y, Nordström A. Traumatic brain injury and young onset dementia: a nationwide cohort study. Ann Neurol. 2014; 75(3): 374-381.
65. Stewart JT. Akathisia following traumatic brain injury: treatment with bromocriptine. J Neurol Neurosurg Psychiatry. 1989; 52(10): 1200-1201.
66. Brown K, Glen S, White T. Low serum iron status and akathisia. Lancet. 1987; 329(8544): 1234-1236.
67. Krieger J, Schroeder C. Iron, brain and restless legs syndrome. Sleep Med Rev. 2001; 5(4): 277-286.
68. Chong SA, Mythily, Remington G. Clinical characteristics and associated factors in antipsychotic-induced akathisia of Asian patients with schizophrenia. Schizophr Res. 2003; 59(1): 67-71.
69. Akagi H, Kumar TM. Lesson of the week: akathisia: overlooked at a cost. BMJ. 2002; 324(7352): 1506-1507.
70. Hirose S. The causes of underdiagnosing akathisia. Schizophr Bull. 2003; 29(3): 547-558.
71. Stahl SM. Akathisia and tardive dyskinesia: changing concepts. Arch Gen Psychiatry. 1985; 42(9): 915-917.
72. Weiden PJ, Mann JJ, Haas G, Mattson M, Frances A. Clinical nonrecognition of neuroleptic-induced movement disorders: a cautionary study. Am J Psychiatry. 1987; 144(9): 1148-1153.
73. Madruga-Garrido M, Mir P. Tics and other stereotyped movements as side effects of pharmacological treatment. In Davide M, Andrea EC eds International Review of Neurobiology. Vol 112. London: Academic Press; 2013: 481-494.
74. Weiden P, Bruun R. Worsening of Tourette's disorder due to neuroleptic-induced akathisia. Am J Psychiatry. 1987; 144(4): 504-505.
75. Fountoulakis KN, Samara M, Siapera M, Iacovides A. Tardive Tourette-like syndrome: a systematic review. Int Clin Psychopharmacol. 2011; 26(5): 237-242.
76. Stahl SM. Tardive Tourette syndrome in an autistic patient after long-term neuroleptic administration. Am J Psychiatry. 1980; 137(10): 1267-1269.
77. Burkhard PR. Acute and subacute drug-inducedmovement disorders. Parkinsonism Relat Disord. 2014; 20(Suppl 1): S108-S112.
78. Dayalu P, Chou KL. Antipsychotic-induced extrapyramidal symptoms and their management. Expert Opin Pharmacother. 2008; 9(9): 1451-1462.
79. Mihanovic M, Bodor D, Kezic S, Restek-Petrovic B, Silic A. Differential diagnosis of psychotropic side effects and symptoms and signs of psychiatric disorders. Psychiatr Danub. 2009; 21(4): 570-574.
80. Rodnitzky RL. Drug-induced movement disorders. Clin Neuropharmacol. 2002; 25(3): 142-152.
81. Sachdev PS. Neuroleptic-induced movement disorders: an overview. Psychiatr Clin North Am. 2005; 28(1): 255-274.
82. Kahn EM, Munetz MR, Davies MA, Schulz SC. Akathisia: Clinical phenomenology and relationship to tardive dyskinesia. Compr Psychiatry. 1992; 33(4): 233-236.
83. Ekbom KA. Asthenia crurum paraesthetica ("irritable legs"). Acta Med Scand. 1944; 118(1-3): 197-209.
84. Trenkwalder C, Paulus W, Walters AS. The restless legs syndrome. Lancet Neurol. 2005; 4(8): 465-475.
85. Angelini M, Negrotti A, Marchesi E, Bonavina G, Calzetti S. A study of the prevalence of restless legs syndrome in previously untreated Parkinson's disease patients: absence of co-morbid association. J Neurol Sci. 2011; 310(1-2): 286-288.
86. Bhalsing K, Suresh K, Muthane UB, Pal PK. Prevalence and profile of restless legs syndrome in Parkinson's disease and other neurodegenerative disorders: a case-control study. Parkinsonism Relat Disord. 2013; 19(4): 426-430.
87. Möller JC, Unger M, Stiasny-Kolster K, Oertel WH. Restless legs syndrome (RLS) and Parkinson's disease (PD)-related disorders or different entities? J Neurol Sci. 2010; 289(1-2): 135-137.
88. Nomura T, Inoue Y, Nakashima K. Clinical characteristics of restless legs syndrome in patients with Parkinson's disease. J Neurol Sci. 2006; 250(1-2): 39-44.
89. Rijsman RM, Schoolderman LF, Rundervoort RS, Louter M. Restless legs syndrome in Parkinson's disease. Parkinsonism Relat Disord. 2014; 20(Suppl 1): S5-S9.
90. Blaisdell GD. Akathisia: a comprehensive review and treatment summary. Pharmacopsychiatry. 1994; 27(4): 139-146.
91. Poewe W, Hogl B. Akathisia, restless legs and periodic limb movements in sleep in Parkinson's disease. Neurology. 2004; 63(8 Suppl 3): S12-S16.
92. Linazasoro G, Massó JFM, Suárez JA. Nocturnal akathisia in Parkinson's disease: treatment with clozapine. Mov Disord. 1993; 8(2): 171-174.
93. Takahashi M, Ikeda J, Tomida T, Hirata K, Hattori N, Inoue Y. Daytime symptoms of restless legs syndrome-clinical characteristics and rotigotine effectiveness. Sleep Med. 2015; 16(7): 871-876.
94. Walters AS, Hening W, Rubinstein M, Chokroverty S. A clinical and polysomnographic comparison of neuroleptic-induced akathisia and the idiopathic restless legs syndrome. Sleep. 1991; 14(4): 339-345.
95. Marsden CD, Jenner P. The pathophysiology of extrapyramidal sideeffects of neuroleptic drugs. Psychol Med. 1980; 10(1): 55-72.
96. Eisensehr I, Ehrenberg BL, Noachtar S. Different sleep characteristics in restless legs syndrome and periodic limb movement disorder. Sleep Med. 2003; 4(2): 147-152.
97. Stahl SM, Loonen AJ. The mechanism of drug-induced akathisia. CNS Spectr. 2011; 16(1): 7-10.
98. Rios Romenets S, Dauvilliers Y, Cochen De Cock V, et al. Restless legs syndrome outside the blood-brain barrier-exacerbation by domperidone in Parkinson's disease. Parkinsonism Relat Disord. 2013; 19(1): 92-94.
99. Barnes TRE. The Barnes Akathisia Rating Scale-Revisited. J Psychopharmacol. 2003; 17(4): 365-370.
100. Lima AR, Weiser KV, Bacaltchuk J, Barnes TR. Anticholinergics for neuroleptic-induced acute akathisia. Cochrane Database Syst Rev. 2004; (1): CD003727.
101. Rathbone J, Soares-Weiser K. Anticholinergics for neurolepticinduced acute akathisia. Cochrane Database Syst Rev. 2006; (4): CD003727.
102. Baskak B, Atbasoglu EC, Ozguven HD, Saka MC, Gogus AK. The effectiveness of intramuscular biperiden in acute akathisia: a double-blind, randomized, placebo-controlled study. J Clin Psychopharmacol. 2007; 27(3): 289-294.
103. Lima AR, Bacalcthuk J, Barnes TR, Soares-Weiser K. Central action beta-blockers versus placebo for neuroleptic-induced acute akathisia. Cochrane Database Syst Rev. 2004; (4): CD001946.
104. Poyurovsky M. Acute antipsychotic-induced akathisia revisited. Br J Psychiatry. 2010; 196(2): 89-91.
105. Berk M, Copolov D, Dean O, et al. N-acetyl cysteine as a glutathione precursor for schizophrenia-a double-blind, randomized, placebocontrolled trial. Biol Psychiatry. 2008; 64(5): 361-368.
106. Guay DRP. Tetrabenazine, a monoamine-depleting drug used in the treatment of hyperkinetic movement disorders. Am J Geriatr Pharmacother. 2010; 8(4): 331-373.
107. Jankovic J, Clarence-Smith K. Tetrabenazine for the treatment of chorea and other hyperkinetic movement disorders. Expert Rev Neurother. 2011; 11(11): 1509-1523.
108. Fehr C, Dahmen N, Klawe C, Eicke M, Szegedi A. Piracetam in the treatment of tardive dyskinesia and akathisia: a case report. J Clin Psychopharmacol. 2001; 21(2): 248-249.